Xavo, a leading provider of Software-as-a-Service for Biopharma R&D with offices in Boston, MA, Bayreuth, Germany and Basel, Switzerland, announced today the release of the latest version of its Lab Operations Management Platform, which is called Xavo R3.
As part of Xavo’s mission to accelerate the Biopharma R&D value chain, Xavo R3, which is offered exclusively as Software-as-a-Service, is transforming Sample Management in Biopharma R&D by addressing the strategic problem of optimally fulfilling demand in the form of material requests based on available finite lab capacity and material inventory. Xavo R3 helps Sample Management groups to consistently deliver the right material in the right format to the right recipient in the right quality to promise on time every time by providing the best combination of functional and non-functional means.
“Xavo R3 is positioned to revolutionize the growing market for Sample Management software solutions, used by scientific services labs in the context of basic research, drug discovery and drug development whose job it is to manage large inventories of small or large molecules and to distribute the right material in the right format to the right recipient in the right quality“, says Reda Bensaid, President and CEO of Xavo. He continues: “As a software platform, Xavo R3 differentiates from other point solutions in the market in the way it connects the dynamically changing demand for material samples with the on-promise/on-time fulfillment of material requests.“
Xavo R3 dramatically improves the ability of Sample Management labs to fulfill demand for R&D materials at the highest quality, to promise on time every time. Furthermore, it helps Sample Management labs achieve higher productivity, flexibility and transparency while reducing compound use, labor cost and increasing quality.